BREATHE BETTER * LIVE BETTER †
For patients with moderate to very severe COPD
BREATHE BETTER * LIVE BETTER †
BREZTRI
* BREZTRI AEROSPHERE ® provided significant improvement in LUNG FUNCTION( morning pre-dose trough FEV1) 43mL vs GLY / FORM( p < 0.0001) and 76mL vs BUD / FORM( unadjusted p < 0.0001, nominally significant) over 24 weeks. 1, 2 ** ¶ † BREZTRI AEROSPHERE ® provided significant improvement in QUALITY OF LIFE( SGRQ response^)-1.62 difference vs GLY / FORM and-1.38 difference vs BUD FORM( p < 0.0001 for both) over 24 weeks( ETHOS secondary endpoint). 2 – 5 **
SCAN THIS CODE TO LEARN MORE OR ORDER SAMPLES
INDICATION: BREZTRI AEROSPHERE ® is indicated as a maintenance treatment to prevent exacerbations and relieve symptoms in adults with moderate, severe, or very severe COPD who require treatment with a combination of ICS, LABA, and LAMA. 2 BREZTRI AEROSPHERE ® is not indicated for the initiation of therapy in COPD. 2
SAFETY: In ETHOS, adverse events that occurred in ≥3 % of patients overall for BREZTRI ® and GLY / FORM were nasopharyngitis, COPD, upper respiratory tract infection, pneumonia and bronchitis. 3 The incidence of confirmed pneumonia was 4.2 % with BREZTRI ® and 2.3 % with GLY / FORM. 2, 3 Please review Product Information
for information on other Precautions and Adverse Effects.
** In the 52-week ETHOS study in 8588 symptomatic patients with moderate to very severe COPD and a history of ≥1 exacerbation in the past year; the primary endpoint of the rate of moderate or severe COPD exacerbations was met. ¶ From a PFT sub-study of ETHOS, in a subset of COPD patients( n = 3088) from the mITT population with a pre-dose FEV1 of < 65 % of predicted normal; 1 ^Defined as a decrease from baseline in the total score on the SGRQ of ≥4 points at week 24; total scores on the SGRQ range from 0 to 100, with lower scores indicating better health-related quality of life. 3 – 5
PBS Information: Authority required( STREAMLINED) for the treatment of COPD. Refer to PBS for full authority information.
PLEASE REVIEW FULL PRODUCT INFORMATION BEFORE PRESCRIBING. PRODUCT INFORMATION AVAILABLE ON REQUEST FROM ASTRAZENECA ON 1800 805 342 OR WWW. ASTRAZENECA. COM. AU / PI OR BY SCANNING THIS QR CODE.
BUD = budesonide; COPD = chronic obstructive pulmonary disease; FEV1 = forced expiratory volume in 1 second; FORM = formoterol; GLY = glycopyrronium; ICS = inhaled corticosteroid; LABA = long-acting beta 2 agonist; LAMA = longacting muscarinic antagonist; mITT = modified Intention to treat; PFT = pulmonary function test; pMDI = pressurised Metered Dose Inhaler; SGRQ = St. George’ s Respiratory Questionnaire. References: 1. Rabe KF et al. Ther Adv Respir Dis. 2021; 15:17534666211034329. 2. BREZTRI AEROSPHERE ® Approved Product Information. 3. Rabe KF et al. N Engl J Med. 2020; 383( 1): 35 – 48. 4. Rabe KF et al. N Engl J Med. 2020; 383( 1): 35 – 48. Supplementary appendix. 5. Martinez FJ et al. Respir Med. 2021; 185:106509. BREZTRI ® and AEROSPHERE ® are registered trademarks of the AstraZeneca group of companies. Registered user AstraZeneca Pty. Ltd. ABN 54 009 682 311. 66 Talavera Road, Macquarie Park, NSW 2113. www. astrazeneca. com. au. For Medical Information enquiries or to report an adverse event or product quality complaint: Telephone 1800 805 342 or via https:// contactazmedical. astrazeneca. com. AU-24218. 3190. January 2026.